Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients With Advanced Solid Tumours

Trial Profile

A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients With Advanced Solid Tumours

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FPX01 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Fusion Pharmaceuticals
  • Most Recent Events

    • 04 Jun 2019 Trial design of this study presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 16 May 2019 According to a Fusion Pharmaceuticals media release , data from this trial will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2019 in Chicago, May 31-June 4.
    • 19 Feb 2019 According to a Fusion Pharmaceuticals media release, first patient was dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top